Non-invasive prenatal diagnosis: Implications for antenatal diagnosis and management of high-risk pregnancies

Seminars in Fetal and Neonatal Medicine

Volumn 13, Issue 2, 2008, Pages 84-90

  Alberry, M S ^a,b   Soothill, P W ^a,c  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b AIN SHAMS UNIVERSITY   (Egypt)

^c UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Fetal DNA; FGR; Non invasive prenatal diagnosis; Placental mRNA; Pre eclampsia; Preterm labour

Indexed keywords

BIOLOGICAL MARKER; NUCLEIC ACID;

ARTICLE; HIGH RISK PREGNANCY; HUMAN; INTRAUTERINE GROWTH RETARDATION; MATERNAL BLOOD; PLACENTA DISORDER; PREECLAMPSIA; PREGNANCY COMPLICATION; PREMATURE LABOR; PRENATAL DIAGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

DNA; FEMALE; FETAL BLOOD; FETAL DISEASES; HUMANS; PLACENTA; PREGNANCY; PREGNANCY, HIGH-RISK; PRENATAL DIAGNOSIS; RNA;

EID: 39149102475     PISSN: 1744165X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.siny.2007.12.006     Document Type: Article

References (69)

1. Williamson C. Molecular biology related to pre-eclampsia. Int Congr Series 1279 (2005) 282-289
2. Lo Y.M., Corbetta N., Chamberlain P.R., et al. Presence of fetal DNA in maternal plasma and serum. Lancet 350 (1997) 485-487
3. Poon L.L., Leung T.N., Lau T.K., and Lo Y.M. Presence of fetal RNA in maternal plasma. Clin Chem 46 (2000) 1832-1834
4. Ng E.K., Tsui N.B., Lau T.K., et al. mRNA of placental origin is readily detectable in maternal plasma. Proc Natl Acad Sci USA 100 (2003) 4748-4753
5. Rijnders R.J., van der Luijt R.B., Peters E.D., et al. Earliest gestational age for fetal sexing in cell-free maternal plasma. Prenat Diagn 23 (2003) 1042-1044
6. Finning K.M., Martin P.G., Soothill P.W., and Avent N.D. Prediction of fetal D status from maternal plasma: introduction of a new noninvasive fetal RHD genotyping service. Transfusion 42 (2002) 1079-1085
7. Chiu R.W., Lui W.B., Cheung M.C., et al. Time profile of appearance and disappearance of circulating placenta-derived mRNA in maternal plasma. Clin Chem 52 (2006) 313-316
8. Lo Y.M. Recent developments in fetal nucleic acids in maternal plasma: implications to noninvasive prenatal fetal blood group genotyping. Transfusion Clin Biol 13 (2006) 50-52
9. Ishihara N., Matsuo H., Murakoshi H., Laoag-Fernandez J.B., Samoto T., and Maruo T. Increased apoptosis in the syncytiotrophoblast in human term placentas complicated by either PET or intrauterine growth retardation. Am J Obstet Gynecol 186 1 (2002) 158-166
10. Lo Y.M., Zhang J., Leung T.N., Lau T.K., Chang A.M., and Hjelm N.M. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 64 (1999) 218-224
11. Alberry M., Maddocks D., Jones M., et al. Free fetal DNA in maternal plasma in anembryonic pregnancies: confirmation that the origin is the trophoblasts. Prenat Diagn 27 5 (2007) 415-418
12. Flori E., Doray B., Gautier E., and Kohler M. Circulating cell-free fetal DNA in maternal serum appears to originate from cyto and syncytio-trophoblastic cells. Case report. Hum Reprod 19 3 (2004) 723-724
13. Masuzaki H., Miura K., Yoshiura K., et al. Detection of cell free placental DNA in maternal plasma: direct evidence from three cases of confined placental mosaicism. J Med Genet 41 (2004) 289-292
14. Wataganara T., Gratacos E., Jani J., et al. Persistent elevation of cell-free fetal DNA levels in maternal plasma after selective laser coagulation of chorionic plate anastomoses in severe midgestational twintwin transfusion syndrome. Am J Obstet Gynecol 192 (2005) 604-609
15. Sibai B., Dekker G., and Kupferminc M. Pre-eclampsia. Lancet 365 (2005) 785-799
16. Lo Y.M.D., Leung T.N., Tein M.S., et al. Quantitative abnormalities of fetal DNA in maternal serum in PET. Clin Chem 45 (1999) 184-188
17. Smid M., Vassallo A., Lagona F., et al. Quantitative analysis of fetal DNA in maternal plasma in pathological conditions associated with placental abnormalities. Ann NY Acad Sci 945 (2001) 132-137
18. Shimada K., Murakami K., Shozu M., Segawa T., Sumitani H., and Inoue M. Sex-determining region Y levels in maternal plasma: evaluation in abnormal pregnancy. J Obstet Gynaecol Res 30 (2004) 148-154
19. Zhong X.Y., Laivuori H., Livingston J.C., et al. Elevation of both maternal and fetal extracellular circulating deoxyribonucleic acid concentrations in the plasma of pregnant women with PET. Am J Obstet Gynecol 184 (2001) 414-419
20. Sekizawa A., Farina A., Koide K., et al. Beta-globin DNA in maternal plasma as a molecular marker of pre-eclampsia. Prenat Diagn 24 9 (2004) 697-700
21. Leung T.N., Zhang J., Lau T.K., Chan L.Y., and Lo Y.M. Increased maternal plasma fetal DNA concentrations in women who eventually develop PET. Clin Chem 47 (2001) 137-139
22. Zhong X.Y., Holzgreve W., and Hahn S. The levels of circulatory cell free fetal DNA in maternal plasma are elevated prior to the onset of PET. Hypertens Pregnancy 21 (2002) 77-83
23. Levine R.J., Qian C., and LeShane E.S. Two-stage elevation of cell-free fetal DNA in maternal sera before onset of PET. Am J Obstet Gynecol 190 (2004) 707-713
24. Farina A., Sekizawa A., Sugito Y., et al. Fetal DNA in maternal plasma as a screening variable for PET. A preliminary nonparametric analysis of detection rate in low-risk non-symptomatic patients. Prenat Diagn 24 (2004) 83-86
25. Swinkels D.W., de Kok J.B., Hendriks J.C., Wiegerinck E., Zusterzeel P.L., and Steegers E.A. Hemolysis, elevated liver enzymes and low platelet count (HELLP) syndrome as a complication of PET in pregnant women increases the amount of cell-free fetal and maternal DNA in maternal plasma and serum. Clin Chem 48 (2002) 650-653
26. Farina A., Sekizawa A., Rizzo N., et al. Cell-free fetal DNA (SRY locus) concentration in maternal plasma is directly correlated to the time elapsed from the onset of PET to the collection of blood. Prenat Diagn 24 (2004) 293-297
27. Illanes S., Parra M., Trebilcock J., et al. Increased free fetal DNA (fffDNA) levels in the plasma of pregnant women in early pregnancy are observed in patients who subsequently develop severe placental disease. Ultrasound Obstet Gynecol 30 4 (2007 Oct) 431
28. Godfrey K.M., and Barker D.J. Fetal nutrition and adult disease. Am J Clin Nutr 71 (2000) 1344-1352
29. Alberry M., and Soothill P. Management of FGR. Arch Dis Child Fetal Neonatal Ed 92 1 (2007) 62-67
30. Smid M., Galbiati S., Lojacono A., et al. Correlation of fetal DNA levels in maternal plasma with Doppler status in pathological pregnancies. Prenat Diagn 26 (2006) 785-790
31. Caramelli E., Rizzo N., Concu M., et al. Cell-free fetal DNA concentration in plasma of patients with abnormal uterine artery Doppler waveform and intrauterine growth restriction-a pilot study. Prenat Diagn 23 (2003) 367-371
32. Sekizawa A., Jimbo M., Saito H., et al. Cell free fetal DNA in the plasma of pregnant women with severe FGR. Am J Obstet Gynecol 188 (2003) 480-484
33. Smith G.C., Shah I., White I.R., Pell J.P., Crossley J.A., and Dobbie R. Maternal and biochemical predictors of spontaneous preterm labour among nulliparous women: a systematic analysis in relation to the degree of prematurity. Int J Epidemiol 35 (2006) 1169-1177
34. Goffinet F. Primary predictors of preterm labour. BJOG 112 1 (2005) 38-47
35. Hassan S.S., Romero R., Berry S.M., et al. Patients with an ultrasonographic cervical length ≤15 mm have nearly a 50% risk of early spontaneous preterm delivery. Am J Obstet Gynecol 182 (2000) 1458-1467
36. Leung T.N., Zhang J., Lau T.K., Hjelm N.M., and Lo Y.M. Maternal plasma fetal DNA as a marker for preterm labour. Lancet 352 9144 (1998) 1904-1905
37. Farina A., LeShane E.S., Romero R., et al. High levels of fetal cell-free DNA in maternal serum: a risk factor for spontaneous preterm delivery. Am J Obstet Gynecol 193 (2005) 421-425
38. Sekizawa A., Jimbo M., Saito H., et al. Increased cell-free fetal DNA in plasma of two women with invasive placenta. Clin Chem 48 (2002) 353-354
39. Lazar L., Nagy B., Ban Z., Nagy G.R., and Papp Z. Presence of cell-free fetal DNA in plasma of women with ectopic pregnancies. Clin Chem 52 8 (2006) 1599-1601
40. Yin A., Ng E.H., Zhang X., He Y., Wu J., and Leung K.Y. Correlation of maternal plasma total cell-free DNA and fetal DNA levels with short term outcome of first-trimester vaginal bleeding. Hum Reprod 22 6 (2007) 1736-1743
41. Sekizawa A., Sugito Y., Iwasaki M., et al. Cell-free fetal DNA is increased in plasma of women with hyperemesis gravidarum. Clin Chem 47 (2001) 2164-2165
42. Zhong X.Y., Holzgreve W., Li J.C., Aydinli K., and Hahn S. High levels of fetal erythroblasts and fetal extracellular DNA in the peripheral blood of a pregnant woman with idiopathic polyhydramnios: case report. Prenat Diagn 20 (2000) 838-841
43. Smid M., Galbiati S., Vassallo A., et al. Fetal DNA in maternal plasma in twin pregnancies. Clin Chem 49 9 (2003 Sep) 1526-1528
44. Ng E.K., Leung T.N., Tsui N.B., et al. The concentration of circulating corticotrophin releasing hormone mRNA in maternal plasma is increased in PET. Clin Chem 49 (2003) 727-731
45. Purwosunu Y., Sekizawa A., Koide K., et al. Cell-free mRNA concentrations of plasminogen activator inhibitor-1 and tissue-type plasminogen activator are increased in the plasma of pregnant women with PET. Clin Chem 53 3 (2007) 399-404
46. Farina A., Sekizawa A., Purwosunu Y., et al. Quantitative distribution of a panel of circulating mRNA in PET versus controls. Prenat Diagn 26 (2006) 1115-1120
47. Zhong X.Y., Gebhardt S., Hillermann R., Tofa K.C., Holzgreve W., and Hahn S. Parallel assessment of circulatory fetal DNA and corticotropin-releasing hormone mRNA in early- and late-onset PET. Clin Chem 51 (2005) 1730-1733
48. Grancha S., Estellés A., Gilabert J., Chirivella M., España F., and Aznar J. Decreased expression of PAI-2 mRNA and protein in pregnancies complicated with intrauterine fetal growth retardation. Thromb Haemost 76 5 (1996) 761-767
49. Zhong X.Y., Holzgreve W., Hoesli I., and Hahn S. Circulatory corticotropin-releasing hormone mRNA concentrations are increased in women with preterm delivery but not in those who respond to tocolytic treatment. Clin Chem 51 3 (2005) 635-636
50. Tjoa M.L., Oudejans C.B., Van Vugt J.M., Blankenstein M.A., and Van W.I. Markers for presymptomatic prediction of PET and intrauterine growth restriction. Hypertens Pregnancy 23 2 (2004) 171-189
51. Diesch C.H., Holzgreve W., Hahn S., and Zhong X.Y. Comparison of activin A and cell-free fetal DNA levels in maternal plasma from patients at high risk for PET. Prenat Diagn 26 13 (2006) 1267-1270
52. Lindqvist P., Grennert L., and Marsal K. Epidermal growth factor in maternal urine: a predictor of intrauterine growth restriction?. Early Hum Dev 56 (1999) 143-150
53. Smith G.C., Shah I., Crossley J.A., et al. Pregnancy-associated plasma protein A and alpha-fetoprotein and prediction of adverse perinatal outcome. Obstet Gynaecol 107 1 (2006) 161-166
54. Bartha J.L., Illanes S., González-Bugatto F., Abdel-Fattah S.A., Mizejewski G.J., and Soothill P.W. Maternal serum transformed alpha-fetoprotein levels in women with intrauterine growth retardation. Fetal Diagn Ther 22 4 (2007) 294-298
55. Audiberta F., Benchimola Y., Benattarb C., Champagnea C., and Frydmana R. Prediction of PET or intrauterine growth restriction by second trimester serum screening and uterine Doppler velocimetry. Fetal Diagn Ther 20 (2005) 48-53
56. Honest H., Bachmann L.M., Gupta J.K., Kleijnen J., and Khan K.S. Accuracy of cervicovaginal fetal fibronectin test in predicting risk of spontaneous preterm labour: systematic review. BMJ 325 (2002) 301-310
57. Goldenberg R.L., Iams J.D., Mercer B.M., et al. The Preterm Prediction Study: the value of new vs standard risk factors in predicting early and all spontaneous preterm labours. Am J Public Health 88 (1998) 233-238
58. Kurkinen-Raty M., Ruokonen A., Vuopala S., et al. Combination of cervical interleukin-6 and -8, phosphorylated insulin-like growth factor-binding protein-1 and transvaginal cervical ultrasonography in assessment of the risk of preterm labour. BJOG 108 8 (2001) 875-881
59. Ramsey P.S., Tamura T., Goldenberg R.L., et al. The preterm prediction study: elevated cervical ferritin levels at 22 to 24 weeks of gestation are associated with spontaneous preterm delivery in asymptomatic women. Am J Obstet Gynecol 186 3 (2002) 458-463
60. Zhong X.Y., Holzgreve W., and Hahn S. Cell-free fetal DNA in the maternal circulation does not stem from the transplacental passage of fetal erythroblasts. Mol Hum Reprod 8 (2002) 864-870
61. Lau T.W., Leung T.N., Chan L.Y., et al. Fetal DNA clearance from maternal plasma is impaired in preeclampsia. Clin Chem 48 (2002) 2141-2146
62. Estellés A., Gilabert J., Keeton M., et al. Altered expression of plasminogen activator inhibitor type 1 in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation. Blood 84 1 (1994 Jul 1) 143-150
63. Goldenberg R.L., Klebanoff M., Carey J.C., et al. Vaginal fetal fibronectin measurements from 8 to 22 weeks' gestation and subsequent spontaneous preterm birth. Am J Obstet Gynecol 183 (2000) 469-475
64. Heath V.C., Daskalakis G., Zagaliki A., Carvalho M., and Nicolaides K.H. Cervicovaginal fibronectin and cervical length at 23 weeks of gestation: relative risk of early preterm delivery. Br J Obstet Gynaecol 107 (2000) 1276-1281
65. Nageotte M.P., Casal D., and Senyei A.E. Fetal fibronectin in patients at increased risk for premature birth. Am J Obstet Gynecol 170 (1994) 20-25
66. Burrus D.R., Ernest J.M., and Veille J.C. Fetal fibronectin, interleukin-6, and C-reactive protein are useful in establishing prognostic subcategories of idiopathic preterm labor. Am J Obstet Gynecol 173 (1995) 1258-1262
67. Nageotte M.P., Hollenbach K.A., Vanderwahl B.A., and Hutch K.M. Oncofetal fibronectin in patients at increased risk for preterm delivery. Am J Obstet Gynecol 166 (1992) 274
68. Peaceman A.M., Andrews W.W., Thorp J.M., et al. Fetal fibronectin as a predictor of preterm birth in patients with symptoms: a multicenter trial. Am J Obstet Gynecol 177 (1997) 13-18
69. Iams J.D., Casal D., McGregor J.A., et al. Fetal fibronectin improves the accuracy of diagnosis of preterm labor. Am J Obstet Gynecol 173 (1995) 141-145